Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the ...
Alector (ALEC) shares rose ~5% on Thursday after the neurology-focused biotech announced its decision to discontinue a ...
Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate administration Co-administration of the RSV and shingles adjuvanted vaccines was ...
LONDON (Reuters) - Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results